Key milestones achieved for kidneyintelX.dkd

Summary by AI BETAClose X

Renalytix plc has achieved key regulatory milestones to support the scaling of its kidneyintelX.dkd test, including the successful transfer of laboratory operations to a new facility in New York which increases testing capacity by over 3.5x and is projected to save over $2.6 million on a net present value basis over five years. Additionally, the company has completed the submission for CE marking of kidneyintelX.dkd, a crucial step for its use in global pharma clinical trials and potential commercialization in European markets, with the CE marking process expected to finalize in Q3 2026.

Disclaimer*

UK 100

Latest directors dealings